Archive — US — techcrunch
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda, a biotech startup focused on AI-driven drug discovery from natural substances, has secured $311 million in Series E funding, elevating its valuation to $2 billion. Founded in 2019, Enveda aims to expedite drug discovery using AI, with ongoing clinical trials for various natural-derived candidates, despite no FDA-approved AI drugs yet.
Key points
- Enveda secured $311 million in Series E funding led by Catalio Capital Management.
- The funding doubled Enveda's valuation to $2 billion in just one year.
- The startup leverages AI to discover drugs from plants and microbes instead of synthetic methods.
- Founded in 2019 by Viswa Colluru, Enveda targets faster drug discovery processes.
- Enveda is currently conducting clinical trials for several drugs, including one for severe skin conditions and another for weight loss maintenance.
Why it matters
- AI in drug discovery is a growing trend, with companies like Moderna and DeepMind also exploring this area.
- The increased funding in biotech startups illustrates a wider interest in nature-derived therapies and sustainable drug development.
- By 2025, integrating AI in drug discovery is expected to revolutionize pharmaceutical innovation and reduce time to market for new therapies.
Enveda's significant funding marks a pivotal advancement in the intersection of AI and natural drug discovery, potentially leading to novel therapeutics and changing the landscape of how medicines are developed.